Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREATH2
2024-517878-21-00Phase 2Completed
- Sponsor
- Military Institute of Medicine – National Research Institute
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19), pneumonia, bacterial pneumonia and 1 more comparing ITPP (OXY111A) + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Improvement of respiratory capacity. Started Jan 2025; status: completed.
02
Drugs
myo-inositol trispyrophosphate
03
Conditions
coronavirus disease 2019 (COVID-19)pneumoniabacterial pneumoniaviral pneumonia
Beyond the preview
Go deeper on 2024-517878-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517878-21-00.